644521

Hill Dermaceuticals, Inc. — FEI 1036365

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
February 19, 2010
Fiscal Year
2010
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Sanford, FL (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)

Citations

IDCFRDescription
108621 CFR 211.22(b)Adequate lab facilities not available
111221 CFR 211.25(a)Training--operations, GMPs, written procedures
127421 CFR 211.68(a)Calibration/Inspection/Checking not done
135821 CFR 211.100(b)SOPs not followed / documented
139521 CFR 211.103Actual vs. theoretical yields not determined
144821 CFR 211.111Establishment of time limitations
150921 CFR 211.122(h)Printing devices
188621 CFR 211.165(c)Sampling and testing plans not described
189021 CFR 211.165(e)Test methods
201721 CFR 211.188(b)(5)In-Process and Laboratory Control Results
202721 CFR 211.192Investigations of discrepancies, failures
203521 CFR 211.194(e)Stability testing records not included
239721 CFR 211.194(a)(1)Description and Identification of Samples
358221 CFR 211.105(a)Identification of containers, lines, equipment
358521 CFR 211.110(a)Control procedures to monitor and validate performance
361521 CFR 211.160(b)(4)Test devices not meeting specifications
363221 CFR 211.170(b)Annual visual exams of drug products
434521 CFR 211.160(b)(1)Samples (various types) representative, identified properly
900121 CFR 211.22(a)Lack of quality control unit